Ajit K Parhi
Overview
Explore the profile of Ajit K Parhi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
352
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sagong H, Rosado-Lugo J, Bryan E, Ferrer-Gonzalez E, Wang Y, Cao Y, et al.
Med Chem Res
. 2023 Apr;
31(10):1679-1704.
PMID: 37077288
MreB is a cytoskeleton protein present in rod-shaped bacteria that is both essential for bacterial cell division and highly conserved. Because most Gram (-) bacteria require MreB for cell division,...
2.
Kaul M, Ferrer-Gonzalez E, Mark L, Parhi A, LaVoie E, Pilch D
Med Chem Res
. 2023 Apr;
31(10):1705-1715.
PMID: 37065467
Oxacillin is a first-line antibiotic for the treatment of methicillin-sensitive (MSSA) infections but is ineffective against methicillin-resistant (MRSA) due to resistance. Here we present results showing that co-administering oxacillin with...
3.
Zhang Y, Rosado-Lugo J, Datta P, Sun Y, Cao Y, Banerjee A, et al.
Antibiotics (Basel)
. 2022 Jun;
11(6).
PMID: 35740123
Efflux pumps in Gram-negative bacteria such as Pseudomonas aeruginosa provide intrinsic antimicrobial resistance by facilitating the extrusion of a wide range of antimicrobials. Approaches for combating efflux-mediated multidrug resistance involve,...
4.
Bryan E, Sagong H, Parhi A, Grier M, Roberge J, LaVoie E, et al.
Antibiotics (Basel)
. 2022 May;
11(5).
PMID: 35625337
The emergence of multi-drug-resistant Gram-negative pathogens highlights an urgent clinical need to explore and develop new antibiotics with novel antibacterial targets. MreB is a promising antibacterial target that functions as...
5.
Rosado-Lugo J, Sun Y, Banerjee A, Cao Y, Datta P, Zhang Y, et al.
J Antibiot (Tokyo)
. 2022 May;
75(7):385-395.
PMID: 35618784
FtsZ inhibitors represent a new drug class as no drugs using this mode of action (MOA) have been approved by regulators. 3-alkoxy substituted 2,6-difluorobenzamide scaffold is one of the most...
6.
Yuan Y, Rosado-Lugo J, Zhang Y, Datta P, Sun Y, Cao Y, et al.
Antibiotics (Basel)
. 2022 Jan;
11(1).
PMID: 35052908
The ability to rescue the activity of antimicrobials that are no longer effective against bacterial pathogens such as is an attractive strategy to combat antimicrobial drug resistance. Herein, novel efflux...
7.
Blankson G, Parhi A, Kaul M, Pilch D, LaVoie E
Bioorg Med Chem
. 2019 Jun;
27(15):3254-3278.
PMID: 31235265
No abstract available.
8.
Blankson G, Parhi A, Kaul M, Pilch D, LaVoie E
Eur J Med Chem
. 2019 Jun;
178:30-38.
PMID: 31173969
Several studies that have identified agents that potentiate the antimicrobial activity of antibiotics, but there are limited insights into their structure-activity relationships (SAR). The SAR associated with select N-alkylaryl amide...
9.
Ferrer-Gonzalez E, Kaul M, Parhi A, LaVoie E, Pilch D
Antimicrob Agents Chemother
. 2017 Jun;
61(9).
PMID: 28630190
Methicillin-resistant (MRSA) is a multidrug-resistant pathogen that poses a significant risk to global health today. We have developed a promising new FtsZ-targeting agent (TXA707) with potent activity against MRSA isolates...
10.
Fujita J, Maeda Y, Mizohata E, Inoue T, Kaul M, Parhi A, et al.
ACS Chem Biol
. 2017 Jun;
12(7):1947-1955.
PMID: 28621933
In the effort to combat antibiotic resistance, inhibitors of the essential bacterial protein FtsZ have emerged as a promising new class of compounds with clinical potential. One such FtsZ inhibitor...